Product image of Kayexalate Sodium (Sodium Polystyrene Sulfonate) supplied by GNH India

Kayexalate Sodium

Active Ingredient:
Sodium Polystyrene Sulfonate
Origin:
EU

Kayexalate Sodium (Sodium Polystyrene Sulfonate)

Sodium Polystyrene Sulfonate, the active ingredient in Kayexalate Sodium, is an ion‑exchange resin presented as an oral/rectal powder for oral and rectal use. It binds excess potassium in the gastrointestinal tract to treat hyperkalemia in patients with elevated serum potassium levels, particularly in acute care settings.

GNH India supplies Kayexalate Sodium as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation to support import and clinical use.

Manufacturer / TM Owner

Sanofi Belgium

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Kayexalate Sodium is used to lower elevated potassium levels in conditions associated with hyperkalemia.

  • Hyperkalemia: reduces serum potassium concentrations to safer levels.
  • Acute potassium overload: facilitates rapid potassium removal in emergency situations.
  • Chronic kidney disease with hyperkalemia: helps maintain potassium balance in patients with reduced renal excretion.

How It Works

  • Sodium Polystyrene Sulfonate is an ion‑exchange resin that remains confined to the gastrointestinal lumen. Its sulfonate groups exchange sodium ions for free potassium ions present in the intestinal contents, forming a bound complex that is not absorbed and is eliminated in the feces, thereby lowering systemic potassium levels.

Side Effects

Kayexalate Sodium may cause gastrointestinal and systemic adverse reactions, which are categorized by frequency and severity.

Common Side Effects

  • Nausea: mild to moderate upset stomach.
  • Vomiting: occasional expulsion of stomach contents.
  • Constipation: reduced bowel movements.
  • Diarrhea: loose stools.
  • Abdominal pain: cramping or discomfort.
  • Flatulence: increased gas.

Serious or Rare Side Effects

  • Intestinal necrosis: tissue death in the bowel.
  • Colonic perforation: a hole in the colon wall.
  • Severe electrolyte disturbances: abnormal sodium or calcium levels.
  • Allergic reactions: rash, itching, or swelling.
  • Hypernatremia: elevated blood sodium concentration.
  • Severe constipation leading to obstruction: blockage of intestinal flow.

Precautions & Warnings

Before prescribing Kayexalate Sodium, clinicians should evaluate patient‑specific factors and monitor for potential complications.

  • Renal function assessment: evaluate kidney function before initiating therapy.
  • Serum potassium monitoring: check potassium levels regularly during treatment.
  • Electrolyte balance: monitor sodium and other electrolytes to avoid imbalances.
  • Gastrointestinal risk: use caution in patients with bowel disorders or recent surgery.
  • Drug interactions: review concomitant medications that may affect potassium.
  • Store at ambient temperature: keep in original container, protect from moisture and heat.

Avoid Interactions

Kayexalate Sodium can interact with several medicines, requiring careful management.

Major Interactions (Avoid)

  • Sodium polystyrene sulfonate with sorbitol: increased risk of colonic necrosis.
  • Concurrent use with potassium‑sparing diuretics: may blunt potassium‑lowering effect.
  • Co‑administration with ACE inhibitors or ARBs: heightened risk of hyperkalemia if resin is ineffective.

Moderate Interactions (Monitor Closely)

  • Antacids containing magnesium or aluminum: may reduce resin binding capacity.
  • Oral iron supplements: may interfere with potassium exchange.
  • Lithium therapy: monitor lithium levels as resin may affect absorption.

Frequently Asked Questions

Kayexalate Sodium is prescribed to lower elevated serum potassium levels in patients with hyperkalemia. It is commonly used in acute care settings, chronic kidney disease, and other conditions where potassium accumulation poses a risk to cardiac and neuromuscular function.

The active resin exchanges sodium ions for free potassium ions in the gastrointestinal tract. The bound potassium is not absorbed and is eliminated with feces, which gradually reduces the amount of potassium circulating in the bloodstream.

The dose of Kayexalate Sodium is individualized by the prescribing clinician based on the severity of hyperkalemia, patient weight, renal function, and concurrent therapies. Dosage forms may be administered orally or rectally as directed by a healthcare professional.

Safety data for sodium polystyrene sulfonate in pregnancy and lactation are limited. Clinicians should weigh potential benefits against unknown risks and consider alternative treatments when possible. Consultation with a maternal‑fetal medicine specialist is recommended.

To place an order, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Kayexalate Sodium is an ion‑exchange resin, whereas alternatives such as patiromer or sodium zirconium cyclosilicate are non‑resin binders with different onset times and side‑effect profiles. Choice of therapy depends on patient tolerance, speed of potassium reduction needed, and potential drug‑drug interactions.

Store Kayexalate Sodium at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture, direct sunlight and excessive heat to maintain resin integrity.

The resin is supplied as a powder that can be mixed with water, fruit juice, or syrup for oral use, or as a rectal suspension. Administration frequency and volume are determined by the prescriber according to the patient’s clinical status.

Serious adverse events include intestinal necrosis, colonic perforation, severe electrolyte disturbances such as hypernatremia, and rare allergic reactions. Prompt medical attention is required if patients experience severe abdominal pain, bleeding, or signs of infection.

Patients with known hypersensitivity to sodium polystyrene sulfonate, those with active gastrointestinal obstruction, recent bowel surgery, or severe constipation should avoid the product. Caution is also advised in individuals with severe renal impairment where alternative therapies may be preferred.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Sodium Polystyrene Sulfonate

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT